A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone
Objective: ODM-104 is a novel non-nitrocatechol catechol-O-methyltransferase (COMT) inhibitor that is undergoing clinical evaluation for Parkinson’s disease (PD). This study investigated the pharmacodynamic effects of…A single center retrospective analysis of Opicapone treatment in 90 Parkinson patients
Objective: To evaluate retrospectively the treatment with the novel COMT-inhibitor opicapone (OPC) in a tertiary Parkinson Center the first year after its approval in Germany…Fasciculations from a cholinesterase inhibitor
Objective: Present and discuss fasciculations in the setting of acetylcholinesterase inhibitors. Background: Specific acetylcholinesterase (AChE) inhibitors (e.g., donepezil, rivastigmine, galantamine) are the current first-line treatment…Intranasal Delivery of Bromocriptine loaded Lipid Nano Carriers for Enhanced Brain Delivery in Parkinson’s disease
Objective: The objective of this research work is to develop a lipid nanocarrier system of Bromocriptine and evaluate its increased efficacy in the management of…A framework to facilitate competence in practice for Parkinson’s Disease Nurse Specialists in the United Kingdom
Objective: To determine if the current Parkinson's Disease Nurse Specialist (PDNS) competency framework 2nd Edition 2008 (1) for nurses working in the management of Parkinson's…Neurological improvement with WTX101 treatment in a Phase 2, multi-center, open label study in Wilson Disease
Objective: The objective of this study was to characterize neurological manifestations in Wilson Disease (WD) patients and describe specific neurological changes after 24 weeks’ treatment…Evaluating long-term effectiveness of carbidopa/levodopa enteral suspension in advanced Parkinson’s Disease patients: PROviDE study design and baseline characteristics
Objective: To evaluate the real-world long-term effectiveness of CLES on advanced PD patients and their caregivers. Background: Carbidopa/levodopa enteral suspension (CLES) was approved in USA…Improving compliance to Parkinsonism’s pharmacotherapy amongst patients attending a Movement Disorders Clinic (MDC)
Objective: To improve patients’ compliance with Parkinsonism's pharmacotherapy to achieve more accurate clinical assessment in an outpatient setting. Background: Patients with Parkinsonism are encouraged to…SYN120 (a Dual 5-HT6/5-HT2A Antagonist) Study to Evaluate Safety, Tolerability and Efficacy in Parkinson’s Disease Dementia (SYNAPSE): Phase 2a Study Results
Objective: To evaluate the safety and preliminary efficacy of SYN120 in patients with Parkinson's disease dementia (PDD). Background: SYN120 is an antagonist of serotonin receptors…Exploring The Role of a Prescribing Pharmacist in the Management of Parkinson’s Disease
Objective: Aims/Objectives A review to explore the role of a pharmacist NMP within the neurology PD multidisciplinary team during a six month period between 1st…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 34
- Next Page »